FI3799885T3 - Lymfosyyttien estoreittien neutralointi - Google Patents
Lymfosyyttien estoreittien neutralointiInfo
- Publication number
- FI3799885T3 FI3799885T3 FIEP20181825.9T FI20181825T FI3799885T3 FI 3799885 T3 FI3799885 T3 FI 3799885T3 FI 20181825 T FI20181825 T FI 20181825T FI 3799885 T3 FI3799885 T3 FI 3799885T3
- Authority
- FI
- Finland
- Prior art keywords
- antibody
- use according
- cancer
- human
- neutralizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (18)
1. Ihmisen NKG2A:ta neutraloiva vasta-aine käytettäväksi ihmispotilaan syövän hoidossa, jolloin hoito käsittää kummankin seuraavista tehokkaan määrän antamisen — potilaalle: (a) vasta-aine, joka neutraloi ihmisen NKG2A:n, ja (b) vasta-aine, joka neutraloi ihmisen PD-1:n.
2. Patenttivaatimuksen 1 mukaisesti käytettävä vasta-aine, jolloin vasta-ainetta, joka neutraloi ihmisen NKG2A:n, annetaan vähintään kaksi annosta määränä, joka — saavuttaa tehokkaasti jatkuvan veren NKGZ2A-vasta-ainepitoisuuden, joka on vähintään 10 pg/ml, vähintään viikon ajan sen antamisen jälkeen.
3. Jommankumman patenttivaatimuksen 1-2 mukaisesti käytettävä vasta-aine, jolloin hoito käsittää vähintään yhden antojakson, jolloin valinnaisesti jakso on — kahdeksan viikon jakso, jolloin kutakin jaksoa kohden annetaan kaksi, kolme tai neljä annosta ihmisen NKG2A:ta neutraloivaa vasta-ainetta ja kaksi, kolme tai neljä annosta PD-1:tä neutraloivaa vasta-ainetta.
4. Patenttivaatimuksen 1-3 mukaisesti käytettävä vasta-aine, jolloin ihmisen NKGZ2A:ta neutraloiva vasta-aine ja PD-1:tä neutraloiva vasta-aine on formuloitu erillistä antamista varten ja ne annetaan samanaikaisesti tai peräkkäin tai ne on formuloitu annettaviksi samanaikaisesti yhtenä formulaationa tai ne on formuloitu annettaviksi samanaikaisesti samana päivänä.
5. Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, jolloin syöpä on kiinteä kasvain tai hematologinen kasvain, edullisesti syöpä, joka on valittu ryhmästä, joka koostuu keuhkosyövästä, munuaissolukarsinoomasta (RCC), melanoomasta, kolorektaalisyövästä ja munasarjasyövästä.
6. Patenttivaatimuksen 5 mukaisesti käytettävä vasta-aine, jolloin syöpä on HLA- E:tä ilmentävä syöpä.
EP3799885
2
7. Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, jolloin syöpä on keuhkosyöpä, edullisesti ei-pienisoluinen keuhkosyöpä.
8. Jonkin edellä olevan patenttivaatimuksen mukaisesti käytettävä vasta-aine, — jolloin mainittu ihmisen NKG2A:ta neutraloiva vasta-aine käsittää raskasketjun CDR1- , CDR2- ja CDR3-domeenit, joiden sekvenssi on jonkin sekvensseistä SEQ ID NO: 4— 8 mukainen, ja kevytketjun CDR1-, CDR2- ja CDR3-domeenit, joiden sekvenssi on sekvenssin SEO ID NO: 9 mukainen.
9. Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, jolloin mainittu vasta-aine on kimeerinen, humaani tai humanisoitu vasta-aine.
10. — Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, jolloin mainittu NKG2A:ta neutraloiva vasta-aine on depleetiota aiheuttamaton vasta- — aine.
11. — Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, jolloin mainittu PD-1:tä neutraloiva vasta-aine on depleetiota aiheuttamaton vasta- aine.
12. — Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, jolloin mainittu vasta-aine on 19G4-vasta-aine.
13. — Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, — jolloin mainitusta vasta-aineesta puuttuu Fc-domeeni tai se käsittää Fc-domeenin, jota on muokattu Fc-domeenin ja Fcy-reseptorin välisen sitoutumisen vähentämiseksi.
14. — Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, jolloin mainittu vasta-aine on vasta-ainefragmentti, jolloin valinnaisesti mainittu vasta- — ainefragmentti on valittu seuraavista: Fab, Fab', Fab'-SH, F(ab')2, Fv, diabody, yksiketjuinen vasta-ainefragmentti tai monispesifinen vasta-aine, joka käsittää useita eri vasta-ainefragmentteja.
EP3799885 3
15. — Jonkin edellä mainitun patenttivaatimuksen mukaisesti käytettävä vasta-aine, jolloin mainittu ihmisen NKG2A:ta neutraloiva vasta-aine käsittää raskasketjun, jolla on sekvenssin SEO ID NO: 5 mukainen sekvenssi, ja kevytketjun, jolla on sekvenssin SEO ID NO: 9 mukainen sekvenssi, ja jolloin mainittu ihmisen PD-1:tä neutraloiva vasta-aine on PD-L1-vasta-aine, joka estää PD-L1:n sitoutumisen PD-1:een.
16. Patenttivaatimuksen 15 mukaisesti käytettävä vasta-aine, jolloin PD-L1-vasta- aine on MEDI-4736.
17. Jonkin patenttivaatimuksen 1-14 mukaisesti käytettävä vasta-aine, jolloin ihmisen NKG2A:ta neutraloiva vasta-aine käsittää raskasketjun, jolla on sekvenssin SEO ID NO: 5 mukainen sekvenssi, ja kevytketjun, jolla on sekvenssin SEO ID NO: 9 mukainen sekvenssi, ja jolloin ihmisen PD-1:tä neutraloiva vasta-aine on valittu ryhmästä, joka koostuu pembrolitsumabista, nivolumabista, AMP-514:stä, MEDI- 4736:sta, CT-011:sta ja MPDL3280A:sta.
18. — Jonkin patenttivaatimuksen 15—17 mukaisesti käytettävä vasta-aine, jolloin syöpä on ei-pienisoluinen keuhkosyöpä.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050948P | 2014-09-16 | 2014-09-16 | |
| US201462083929P | 2014-11-25 | 2014-11-25 | |
| US201462093141P | 2014-12-17 | 2014-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3799885T3 true FI3799885T3 (fi) | 2025-10-15 |
Family
ID=54147180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20181825.9T FI3799885T3 (fi) | 2014-09-16 | 2015-09-15 | Lymfosyyttien estoreittien neutralointi |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10711063B2 (fi) |
| EP (3) | EP4368205A1 (fi) |
| JP (2) | JP6767362B2 (fi) |
| KR (3) | KR102543739B1 (fi) |
| CN (2) | CN107001466B (fi) |
| AU (1) | AU2015316991B2 (fi) |
| CA (1) | CA2957491A1 (fi) |
| CY (1) | CY1123827T1 (fi) |
| DK (2) | DK3799885T3 (fi) |
| ES (1) | ES2825576T3 (fi) |
| FI (1) | FI3799885T3 (fi) |
| HR (1) | HRP20201656T1 (fi) |
| HU (1) | HUE051193T2 (fi) |
| IL (1) | IL250587B (fi) |
| LT (1) | LT3193931T (fi) |
| MX (1) | MX386789B (fi) |
| PL (1) | PL3193931T3 (fi) |
| PT (2) | PT3799885T (fi) |
| RS (1) | RS60935B1 (fi) |
| RU (1) | RU2734771C2 (fi) |
| SG (2) | SG11201701340RA (fi) |
| SI (1) | SI3193931T1 (fi) |
| SM (1) | SMT202000562T1 (fi) |
| WO (1) | WO2016041945A1 (fi) |
| ZA (1) | ZA201702642B (fi) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| CN103635487B (zh) | 2011-06-17 | 2016-10-12 | 诺沃—诺迪斯克有限公司 | 选择性消除侵蚀性细胞 |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| SG11201701387SA (en) | 2014-09-16 | 2017-03-30 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| EP4368205A1 (en) | 2014-09-16 | 2024-05-15 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| WO2016062851A1 (en) | 2014-10-23 | 2016-04-28 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| SI3405495T1 (sl) * | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
| SG11201900138TA (en) * | 2016-07-07 | 2019-02-27 | Iovance Biotherapeutics Inc | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| DE102017001875A1 (de) * | 2017-02-27 | 2018-08-30 | Wolfgang Würfel | Medikament zur Malignombehandlung |
| JP2020527144A (ja) * | 2017-07-10 | 2020-09-03 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法 |
| ES3032734T3 (en) | 2017-10-27 | 2025-07-24 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| JP2021509586A (ja) | 2018-01-08 | 2021-04-01 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍抗原特異的ｔ細胞について濃縮されたｔｉｌ製品を生成するためのプロセス |
| WO2019175182A1 (en) | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| EP3793607A1 (en) | 2018-05-15 | 2021-03-24 | MedImmune Limited | Treatment of cancer |
| CN110563842B (zh) * | 2018-06-06 | 2022-07-29 | 浙江博锐生物制药有限公司 | 针对程序性死亡配体(pd-l1)的抗体及其应用 |
| TW202035447A (zh) * | 2018-07-04 | 2020-10-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎雙特異性促效性4-1bb抗原結合分子 |
| TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CN114214430B (zh) * | 2021-12-20 | 2024-11-12 | 安徽中盛溯源生物科技有限公司 | Nkg2a在检测小鼠人源肿瘤模型中人nk细胞中的应用 |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2024197157A1 (en) | 2023-03-21 | 2024-09-26 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| CN101899114A (zh) * | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| PT1648507T (pt) * | 2003-07-24 | 2017-03-20 | Innate Pharma Sa | Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk |
| CN101107269B (zh) * | 2004-12-28 | 2012-10-31 | 依奈特制药公司 | 抗nkg2a的单克隆抗体 |
| EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| PL2242773T3 (pl) | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2927240A1 (en) * | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| ES2592216T3 (es) * | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| CN103635487B (zh) | 2011-06-17 | 2016-10-12 | 诺沃—诺迪斯克有限公司 | 选择性消除侵蚀性细胞 |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| AU2015307316A1 (en) | 2014-08-28 | 2017-03-09 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | CD94/NKG2A and/or CD94/NKG2B antibody, vaccine combinations |
| SG11201701387SA (en) | 2014-09-16 | 2017-03-30 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| EP4368205A1 (en) | 2014-09-16 | 2024-05-15 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| WO2016062851A1 (en) | 2014-10-23 | 2016-04-28 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| SI3405495T1 (sl) | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
-
2015
- 2015-09-15 EP EP23220008.9A patent/EP4368205A1/en active Pending
- 2015-09-15 CA CA2957491A patent/CA2957491A1/en active Pending
- 2015-09-15 EP EP20181825.9A patent/EP3799885B1/en active Active
- 2015-09-15 KR KR1020177008164A patent/KR102543739B1/ko active Active
- 2015-09-15 PL PL15766120T patent/PL3193931T3/pl unknown
- 2015-09-15 KR KR1020237019571A patent/KR102748822B1/ko active Active
- 2015-09-15 EP EP15766120.8A patent/EP3193931B1/en active Active
- 2015-09-15 RS RS20201241A patent/RS60935B1/sr unknown
- 2015-09-15 CN CN201580050070.0A patent/CN107001466B/zh active Active
- 2015-09-15 HR HRP20201656TT patent/HRP20201656T1/hr unknown
- 2015-09-15 SI SI201531389T patent/SI3193931T1/sl unknown
- 2015-09-15 PT PT201818259T patent/PT3799885T/pt unknown
- 2015-09-15 RU RU2017105118A patent/RU2734771C2/ru active
- 2015-09-15 CN CN202111217074.7A patent/CN113929782B/zh active Active
- 2015-09-15 LT LTEP15766120.8T patent/LT3193931T/lt unknown
- 2015-09-15 MX MX2017003303A patent/MX386789B/es unknown
- 2015-09-15 DK DK20181825.9T patent/DK3799885T3/da active
- 2015-09-15 JP JP2017514484A patent/JP6767362B2/ja active Active
- 2015-09-15 DK DK15766120.8T patent/DK3193931T3/da active
- 2015-09-15 SG SG11201701340RA patent/SG11201701340RA/en unknown
- 2015-09-15 HU HUE15766120A patent/HUE051193T2/hu unknown
- 2015-09-15 SG SG10202008228XA patent/SG10202008228XA/en unknown
- 2015-09-15 PT PT157661208T patent/PT3193931T/pt unknown
- 2015-09-15 ES ES15766120T patent/ES2825576T3/es active Active
- 2015-09-15 SM SM20200562T patent/SMT202000562T1/it unknown
- 2015-09-15 FI FIEP20181825.9T patent/FI3799885T3/fi active
- 2015-09-15 AU AU2015316991A patent/AU2015316991B2/en active Active
- 2015-09-15 WO PCT/EP2015/071069 patent/WO2016041945A1/en not_active Ceased
- 2015-09-15 US US15/511,778 patent/US10711063B2/en active Active
- 2015-09-15 KR KR1020247042576A patent/KR20250007689A/ko active Pending
-
2017
- 2017-02-14 IL IL250587A patent/IL250587B/en unknown
- 2017-04-12 ZA ZA2017/02642A patent/ZA201702642B/en unknown
-
2020
- 2020-05-13 JP JP2020084652A patent/JP2020147572A/ja not_active Withdrawn
- 2020-07-09 US US16/924,288 patent/US11572410B2/en active Active
- 2020-10-14 CY CY20201100970T patent/CY1123827T1/el unknown
-
2023
- 2023-02-06 US US18/164,649 patent/US20230235060A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| AU2013327116B2 (en) | Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer | |
| RU2014147867A (ru) | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов | |
| IL265541B2 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
| JP2017524715A5 (fi) | ||
| PH12018502623B1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| IL253462B (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
| CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
| JP2019536806A5 (fi) | ||
| JP2015532292A5 (fi) | ||
| NZ740686A (en) | Therapeutic cd47 antibodies | |
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| JP2014512809A5 (fi) | ||
| FI3805268T3 (fi) | Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a | |
| JP2018508483A5 (fi) | ||
| FI3778641T3 (fi) | Bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:tä, ja niiden käyttöjä | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2017514795A5 (fi) | ||
| JP2016537383A5 (fi) | ||
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| JP2016536361A5 (fi) |